Evidence map›Paper›PMID 25161229›Full record

ArticleBioinformatics (Oxford, England)2014

Personalized identification of altered pathways in cancer using accumulated normal tissue data.

TaeJin Ahn, Eunjin Lee, Nam Huh, Taesung Park

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Genomic Analysis of Abnormal DNAM Methylation in Parathyroid Tumors.International journal of endocrinology · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Crosstalk analysis of dysregulated pathways in preeclampsia.Experimental and therapeutic medicine · 2019
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

TaeJin AhnSamsung Advanced Institute of Technology, 130, Suwon-si, Gyeonggi-do, 443-803, Korea, Samsung Genome Institute, Seoul, 135-710, Korea, Interdisciplinary Program in Bioinformatics and Department of Statistics, Seoul National University, Seoul, South Korea Samsung Advanced Institute of Technology, 130, Suwon-si, Gyeonggi-do, 443-803, Korea, Samsung Genome Institute, Seoul, 135-710, Korea, Interdisciplinary Program in Bioinformatics and Department of Statistics, Seoul National University, Seoul, South Korea Samsung Advanced Institute of Technology, 130, Suwon-si, Gyeonggi-do, 443-803, Korea, Samsung Genome Institute, Seoul, 135-710, Korea, Interdisciplinary Program in Bioinformatics and Department of Statistics, Seoul National University, Seoul, South Korea.
Eunjin LeeSamsung Advanced Institute of Technology, 130, Suwon-si, Gyeonggi-do, 443-803, Korea, Samsung Genome Institute, Seoul, 135-710, Korea, Interdisciplinary Program in Bioinformatics and Department of Statistics, Seoul National University, Seoul, South Korea Samsung Advanced Institute of Technology, 130, Suwon-si, Gyeonggi-do, 443-803, Korea, Samsung Genome Institute, Seoul, 135-710, Korea, Interdisciplinary Program in Bioinformatics and Department of Statistics, Seoul National University, Seoul, South Korea.
Nam HuhSamsung Advanced Institute of Technology, 130, Suwon-si, Gyeonggi-do, 443-803, Korea, Samsung Genome Institute, Seoul, 135-710, Korea, Interdisciplinary Program in Bioinformatics and Department of Statistics, Seoul National University, Seoul, South Korea.
Taesung ParkSamsung Advanced Institute of Technology, 130, Suwon-si, Gyeonggi-do, 443-803, Korea, Samsung Genome Institute, Seoul, 135-710, Korea, Interdisciplinary Program in Bioinformatics and Department of Statistics, Seoul National University, Seoul, South Korea Samsung Advanced Institute of Technology, 130, Suwon-si, Gyeonggi-do, 443-803, Korea, Samsung Genome Institute, Seoul, 135-710, Korea, Interdisciplinary Program in Bioinformatics and Department of Statistics, Seoul National University, Seoul, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

motivationIdentifying altered pathways in an individual is important for understanding disease mechanisms and for the future application of custom therapeutic decisions. Existing pathway analysis techniques are mainly focused on discovering altered pathways between normal and cancer groups and are not suitable for identifying the pathway aberrance that may occur in an individual sample. A simple way to identify individual's pathway aberrance is to compare normal and tumor data from the same individual. However, the matched normal data from the same individual are often unavailable in clinical situation. Therefore, we suggest a new approach for the personalized identification of altered pathways, making special use of accumulated normal data in cases when a patient's matched normal data are unavailable. The philosophy behind our method is to quantify the aberrance of an individual sample's pathway by comparing it with accumulated normal samples. We propose and examine personalized extensions of pathway statistics, overrepresentation analysis and functional class scoring, to generate individualized pathway aberrance score.

resultsCollected microarray data of normal tissue of lung and colon mucosa are served as reference to investigate a number of cancer individuals of lung adenocarcinoma (LUAD) and colon cancer, respectively. Our method concurrently captures known facts of cancer survival pathways and identifies the pathway aberrances that represent cancer differentiation status and survival. It also provides more improved validation rate of survival-related pathways than when a single cancer sample is interpreted in the context of cancer-only cohort. In addition, our method is useful in classifying unknown samples into cancer or normal groups. Particularly, we identified 'amino acid synthesis and interconversion' pathway is a good indicator of LUAD (Area Under the Curve (AUC) 0.982 at independent validation). Clinical importance of the method is providing pathway interpretation of single cancer, even though its matched normal data are unavailable. AVAILABILITY AND IMPLEMENTATION: The method was implemented using the R software, available at our Web site: http://bibs.snu.ac.kr/ipas. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Indexed as

AdenocarcinomaAdenocarcinoma of LungColonColonic NeoplasmsGene Expression ProfilingHumansLungLung NeoplasmsNeoplasmsSurvival Analysis

Identifiers

PMID25161229
PMCPMC4147902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.